Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.
Fenk R, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kroger N, Boquoi A, Lopez D, Gerrlich C, Baier J, Liesenjohann S, Hauck K, Savickaite I, Mai EK, Aul C, Strapatsas J, Dienst A, Kondakci M, Haas R, Kobbe G. Fenk R, et al. Among authors: kroger n. Clin Cancer Res. 2020 Nov 15;26(22):5879-5886. doi: 10.1158/1078-0432.CCR-20-0841. Epub 2020 Aug 17. Clin Cancer Res. 2020. PMID: 32817078
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR. Kröger N, et al. Blood. 2002 Dec 1;100(12):3919-24. doi: 10.1182/blood-2002-04-1150. Epub 2002 Aug 8. Blood. 2002. PMID: 12393448 Free article. Clinical Trial.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Schönland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, La Nasa G, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G; Chronic Leukemia Working Party; Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation. Schönland SO, et al. Among authors: kroger n. Blood. 2006 Mar 15;107(6):2578-84. doi: 10.1182/blood-2005-06-2462. Epub 2005 Nov 17. Blood. 2006. PMID: 16293611 Free article.
944 results